Floatz logo

PI3K/MTOR INHIBITOR LY3023414

Juvenile Xanthogranuloma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Juvenile Xanthogranuloma cohort.

Asset / SponsorPhaseRating
ag-120
National Cancer Institute (NCI)
Phase 2CCC
Selpercatinib
National Cancer Institute (NCI)
Phase 2CCC
Ensartinib
National Cancer Institute (NCI)
Phase 2CCC
Palbociclib
National Cancer Institute (NCI)
Phase 2CCC
Tazemetostat
National Cancer Institute (NCI)
Phase 2CCC

View all 12 →

Same molecule, other indications

PI3K/MTOR INHIBITOR LY3023414 is also rated in:

rhabdoid tumorDormant
B
Indicative ·
57 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
57 / 100
View asset →
Langerhans cell histiocytosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →